The maintenance of p-adrenoreceptor blockade is appropriate after surgery (Villers et al., 1984) when sympathetic overactivity occurs in patients with hypertension, coronary artery disease, or both. p-Adrenoreceptor blocking agents reduce the oxygen demand of the heart by decreasing the rate-pressure product and by depressing contractility. However, pure P-adrenoreceptor blocking agents increase systemic vascular resistance (SVR) because of a decrease in cardiac output (CO) and unopposed a-adrenoreceptor stimulation (Ulrych et al., 1968) . Labetalol is a combined a-and p-adrenoreceptor blocking agent (Brogden et al., 1978) which may be of more value than propranolol in the acute treatment of hypertension. It has already been used at induction of (Fischler et al., 1985) , during and after anaesthesia (Meretoja et al., 1980; Morel, Forster and Suter, 1982; Dagnino and Prys-Roberts, 1985) . Pharmacodynamic and pharmacokinetic data on the i.v. infusion of labetalol during the postoperative period have been published (Dagnino and PrysRoberts, 1985) , but no study has been performed in which such data have been collected after a loading dose and maintenance infusion rate of labetalol.
PATIENTS AND METHODS
Six patients (mean age 57 yr, range 30-73, mean weight 64 kg, SD 9) underwent aortobifemoral bypass surgery. Informed consent was obtained from each patient. All patients were given diazepam 10 mg by mouth 2h before induction of (-32 ±11 %) . in heart rate (-20± 11 %) The study was conducted 15 ± 2 h after the end of surgery when the patients were normothermic and once the trachea had been extubated. At the time of the study the patients had normal blood-gas tensions and adequate analgesia, which was produced by extradural morphine 0.05 mg kg" 1 administered when pain appeared at least 4 h after the last systemic injection of narcotic. The persistence of a mean arterial pressure (MAP) greater than 120 mm Hg, associated with cardiac index (CI) greater than 2 litre min" 1 m~2, led to the decision to administer labetalol. A loading dose of labetalol 1.5 mg kg" 1 i.v. was injected to a peripheral vein over 5 min. The procedure allowed for the loading dose to be stopped at 2 min if MAP decreased to less than 80 mm Hg. A maintenance infusion rate of 0.2 mg kg" 1 h" 1 was started 30 min later and maintained for 5.5 h. This infusion rate was calculated on the basis of a total body clearance (C/) of 20 ml kg" 1 min" 1 (McNeil and Louis, 1984) , in order to produce a C of 170 ng ml" 1 as follows (Mitenko and Ogilvie, 1972; Wagner, 1974) : maintenance infusion rate = 0**01.
The following haemodynamic variables were measured: MAP, heart rate (HR), right atrial pressure (RAP), pulmonary arterial pressure (PAP) and pulmonary artery wedge pressure (PWP). CO was determined by the thermodilution method. Cardiac index (CI), stroke volume index (SI), systemic vascular resistance (SVR), pulmonary vascular resistance (PVR) and left ventricular stroke work index (LVSWI) were calculated. Measurements were repeated before and 5, 15, 30, 60, 120, 180, 240 , 300 and 360 min after the labetalol loading dose. Blood samples for plasma labetalol measurement were collected from the radial artery before the administration of labetalol, at the end of the injection of the loading dose and from then on, simultaneously with haemodynamic measurements. Blood samples were centrifuged immediately and the plasma and red cells separated. Plasma was stored at -25 °C. Plasma drug concentrations were measured by a fluorimetric method . Labetalol clearance was calculated by dividing the infusion rate by the measured C" for each patient.
Data were expressed as mean values ± SD. For statistical analysis, an analysis of variance and the Student's paired t test were used.
RESULTS
All patients received the full loading dose of labetalol. The haemodynamic data are summarized in figure 1 and table I and the individual  results concerning CI and SI in table II and SVR  in table III . At the time of the control measurements, CI was increased, but calculated SVR and right and left ventricular filling pressures were within their normal ranges. Labetalol i.v. induced a significant (P < 0.05) mean decrease in MAP (-32± 11 %), in HR (-20± 11 %) ( fig. 1 ) and in CI (-26±15%) (table II) 7±2  7±3  6±4  8±5  6±5  6±6  6±4  5±6  7±6  21±5 19±6 18±5 18±5 18±4 20±6 19±4 20±5 21±7 22±6 2.4±0.6 2.2±0.4 2.2±0.6 2.5±0.3 2.6±0.8 3.0±l.l 2.7±0.8 3.2±0.6 3.3±0.9 2.8±0.4 loading dose and these changes persisted throughout the continuous infusion. A decrease in CI in all six patients was accompanied by a decrease in SI in patients 1, 5 and 6, but no change in the other three (table II) . Within 5 min, the changes in SVR induced by labetalol were no longer uniform (table III) , but at 3 h, SVR had decreased in all patients. The mean decrease in SVR (-22±16%) was significant (P < 0.05) (table III) . Neither ventricular filling pressures nor PVR were greatly affected by labetalol administration ( fig. 1, table I ). Labetalol reduced LVSWI by 40% ( fig. 1 ). Plasma labetalol concentrations ( fig. 2) decreased rapidly after the loading dose, but a tween 2 and 6 h. The individual coefficients of variation of plasma concentrations measured between 2 and 6 h did not exceed 15 %. The labetalol clearance calculated under stable infusion conditions ranged between 10.9 and 15.9 ml kg" 1 stable mean concentration of 264 ± 46 ng ml * was min" 1 (mean 13.1+ 2.4). There was no correlation recorded within 2 h. There were no significant variations in plasma labetalol concentration bebetween the haemodynamic effects of labetalol and plasma concentrations.
DISCUSSION
Labetalol has been used previously in the treatment of postoperative hypertension (Meretoja et al., 1980; Morel, Forster and Suter, 1982; Dagnino and Prys-Roberts, 1985) . However, the only study (Meretoja et al., 1980) which investigated the haemodynamic effects of labetalol in postoperative hypertension showed differences compared with reports of its use in essential hypertension (Koch, 1977; Dunn et al., 1983) . The cardiac effects of labetalol in the present series are similar to those recorded in the previous study (Meretoja et al., 1980) after coronary artery surgery. It appeared to have the same features as other P-adrenergic blocking agents (Ulrych et al., 1968; Burt and Foex, 1979) . It reduced CI in direct proportion to the decrease in HR. Although mean SI was not significantly affected, it decreased in three patients and the decrease in LVSWI observed without a simultaneous reduction in PCWP in all the patients confirmed that labetalol decreased contractility (Meretoja et al., 1980) . No increase in SVR was induced by labetalol. In contrast, when pure P-adrenergic blocking agents were injected i.v. the decrease in CO was associated widi increased SVR (Ulrych et al., 1968; Burt and Foex, 1979; Taylor, Silke and Lee, 1982) . Contrary to what was seen by Meretoja and colleagues (1980) during the postoperative period, we noted systemic arteriolar dilatation in one of the six patients. This decrease in SVR agrees with the findings obtained after the acute administration of labetalol in hypertensive patients (Koch, 1977; Dunn et al., 1983) . This is attributable to the additional property of labetalol (Brogden et al., 1978) which blocks the ot-receptor increase induced by the P 2 -blockade. This action of labetalol increases the antihypertensive effect produced by a decrease in CO. However, this ablocking effect is weaker than the P-blockade and is consistent with animal studies which noted that labetalol is an oc-adrenoreceptor antagonist two to seven times less potent than phentolamine (Farmer et al., 1972; Brittain and Levy, 1976) and with the reports in man where it was found that the p-adrenoreceptor blocking effect of the drug is greater than that of the a-adrenoreceptor action, in the ratio of approximately 3:1 (Richards, Tuckman and Prichard, 1976) .
In the present study we started the labetalol administration after complete rewarming and we excluded patients with left ventricular dysfunction and hypovolaemia in order to avoid the deleterious haemodynamic effects of P-receptor blockade. All patients responded to the loading dose of labetalol and its efficacy may be explained in terms of their increased CI before treatment. This is consistent with the results of Morel, Forster and Suter (1982) who noted a more marked decrease in arterial pressure with labetalol in patients with increased sympathetic drive.
Despite its large volume of distribution (11 litre kg" 1 ) (McNeil and Louis, 1984) , its high hepatic and total body clearance (McNeil and Louis, 1984) make labetalol a most suitable drug for continuous infusion (Dagnino and PrysRoberts, 1985) . However, a delay always exists between starting an infusion and the establishment of steady state conditions. This can be considered to occur in 3.3 half-lives (Rowland and Tozer, 1980) and would take approximately 13 h of constant infusion of labetalol to achieve. The bolus dose given before the start of the infusion enabled this to be attained more rapidly. Such a method has already been described for propranolol (Villers et al., 1984; McAllister, 1976) , but never for labetalol. The loading dose was not selected on known pharmacokinetic values, it was an empirical dose used generally in clinical practice (McNeil and Louis, 1984) ; we obtained the peak effect within 5 min. Thirty minutes after this initial infusion, the slower infusion maintained a stable plasma concentration of the drug up to 6 h. The maintenance infusion rate was not started immediately after the loading dose in order to be sure that the maximal effect of the initial injection had been seen. It has been reported that a plasma concentration of 150-220 ng ml" 1 is necessary to provide adequate betaadrenoreceptor blockade (Prys-Roberts, 1984) . On the basis of the pharmacokinetic results of previous studies, the correct infusion rate to maintain a C* of 170 ng ml" 1 has been determined as 0.20 mg kg" 1 h" 1 using the method described by Mitenko and Ogilvie (1972) and Wagner (1974) . The calculated infused dose used in the present study maintained plasma labetalol concentration above the predicted value which indicates that the clearance value used to determine the maintenance infusion rate was not quite correct. Indeed, the calculation of clearance indicated a value lower than that quoted by McNeil and Louis (1984) . Thus, with this calculated value of clearance, the infusion rate required to maintain a C of ^OngmT 1 would appear to be 0.13 mg kg" 1 h" 1 . Dagnino and Prys-Roberts (1985) demonstrated that, in patients presented for aortic replacement surgery, an infusion rate of 0.15 mg kg" 1 h" 1 produced a significant decrease in the response to isoproterenol; the chronotropic dose 25 was 95 ug. In our patients, this C" was obtained in the absence of bradycardia, hypotension or myocardial failure as shown by haemodynamic stability during the infusion. This fact may be explained by the high degree of resting sympathetic drive inducing tachycardia and hypertension during the control period. We advocate that the infusion be started at a lower rate (between 0.07 and 0.15 mgkg" 1 min~l) and be increased only if hypertension and tachycardia are still present. A lower infusion rate is especially necessary in patients with poorly documented or altered left ventricular function or abnormal liver function.
In contrast to other reports (Richards et al., 1977; McNeil and Louis, 1984) we did not observe any correlation between plasma concentrations and changes in HR or MAP. The main reasons are the dose, which was the same for all patients and induced the same degree of haemodynamic change, and the lack of any quantitation of the degree of P-adrenoreceptor blockade with the isoproterenol dose-response (Dagnino and Prys-Roberts, 1985) .
It is concluded that labetalol is a very effective antihypertensive agent during the postoperative period. The hypotensive effect is produced mainly by a decrease in CO caused by a decrease in HR without increasing SVR. This clearly contrasts with the effect of pure p-adrenoreceptor blocking agents. Although labetalol neither significantly decreased mean SI nor increased ventricular filling pressures, it had a negative inotropic effect which necessitated normal ventricular function for the doses used in the present series. The method of administration used in this study, combining a loading dose and a constant infusion, offers the potential for a rapid and stable haemodynamic effect, but the calculation of the infusion rate must be based on a clearance of 13 ml kg" 1 mm
